Search

Displaying results 3301 - 3310 of 10000 in total
  1. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering … the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia.

  2. Drug

    Hypochlorous acid

    go.drugbank.com/drugs/DB14135
    Investigational

    An oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent.

    Mixtures: K-100, K-100Products: Tok and Care Sanitizer, CELA No-clean hypochlorous acid disinfectant
  3. Drug

    M1-c6v1

    go.drugbank.com/drugs/DB18596
    Investigational

    M1-c6v1 is a recombinant oncolytic virus.

  4. Target

    Heat shock protein 105 kDa

    go.drugbank.com/bio_entities/BE0009029
    TargetHumans

    Acts as a nucleotide-exchange factor (NEF) for chaperone proteins HSPA1A and HSPA1B, promoting the release of ADP from HSPA1A/B thereby triggering client/substrate protein release (PubMed:24318877). Prevents the aggregation of denatured ...

    Polypeptides: Heat shock protein 105 kDa
  5. Target

    Tumor susceptibility gene 101 protein

    go.drugbank.com/bio_entities/BE0019070
    TargetHumans

    Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs).

    Polypeptides: Tumor susceptibility gene 101 protein
  6. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  7. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  8. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system. … Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: PMS-nylidrin Tab 6mg
  9. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer

    Synonyms: MT-I
  10. Drug

    Becotatug vedotin

    go.drugbank.com/drugs/DB17407
    Investigational

    MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.